Sepsis, week 38 edition

The prospective multicenter PROGRESS randomized trial enrolled 1,373 patients with suspected sepsis and compared droplet digital PCR with standard care in a 3:1 allocation. Pathogen-detection positivity was substantially higher with droplet digital PCR than with standard care, 54.1% versus 21.6%. The study directly evaluates a molecular strategy intended to improve pathogen identification and support more targeted antimicrobial management.

Impact: This is one of the week’s strongest practice-oriented studies because it uses a prospective multicenter randomized design to test a diagnostic technology that could alter antibiotic selection and de-escalation. The large sample and direct standard-care comparator improve relevance, although clinical outcome and implementation data remain incomplete.

Clinical Implications: Droplet digital PCR may enable faster and more sensitive pathogen detection and could support earlier antimicrobial refinement. Routine adoption should await evidence on turnaround time, antibiotic exposure, mortality, costs, pathogen-specific performance, and laboratory feasibility across healthcare systems.

This translational study used spatial metabolomics and proteomics to map kidney injury during sepsis and identified increased ARG2 expression in renal tubular cells and macrophages. Pharmacologic ARG2 inhibition and renal tubule-specific knockdown reduced tubular lipid accumulation, improved real-time glomerular filtration rate, and lowered blood urea nitrogen, with restoration of PPARγ signaling implicated as a mechanism. Findings from primary cells and human kidney organoids provided additional mechanistic support.

Impact: The paper moves sepsis-associated acute kidney injury research from descriptive injury markers toward a spatially defined metabolic mechanism and a testable therapeutic target. Its convergence of multi-omics, genetic and pharmacologic intervention, cellular experiments, and human organoids makes ARG2 one of the week’s most compelling translational targets.

Clinical Implications: ARG2 inhibition could eventually support prevention or treatment of sepsis-associated acute kidney injury, but the optimal therapeutic window, tissue selectivity, effects on systemic arginine metabolism, host defense, and long-term safety remain unknown. Clinical translation requires validation in multiple clinically relevant sepsis models before human trials.

This preclinical study developed nanoparticles that selectively delivered stabilized FOXF1 mRNA to pulmonary endothelial cells in neonatal mice with lipopolysaccharide-induced pediatric acute respiratory distress syndrome. Treatment reduced vascular leakage and endothelial apoptosis, improved barrier function, and increased survival. Restoration of BCL2 expression was identified as a possible mechanism linking FOXF1 delivery to endothelial protection.

Impact: This study offers a disease-modifying strategy for pediatric sepsis-associated lung injury by restoring a lung-repair transcription factor directly in the injured endothelial compartment. The combination of cell-selective delivery, mechanistic validation, and survival improvement makes it a notable paradigm-shifting preclinical advance.

Clinical Implications: FOXF1 mRNA nanoparticles could eventually complement respiratory support in pediatric acute lung injury, but human use is premature. Biodistribution, dosing, repeat administration, immune effects, manufacturing, long-term toxicity, and efficacy in polymicrobial sepsis models must be established before clinical translation.